FDA agrees 200-patient Phase 3 design for REC-4881 in FAP
Recursion's FDA-agreed 200-patient Phase 3 design for REC-4881 counts 10-mm-plus adenoma removals as events; the FAP trial is planned to start in 2H 2027.

U/PIPELINE
4 filings logged
Clinical-stage assets and trial readouts — Phase I to registration, endpoints, outcomes and pipeline strategy.
Recursion's FDA-agreed 200-patient Phase 3 design for REC-4881 counts 10-mm-plus adenoma removals as events; the FAP trial is planned to start in 2H 2027.
